Research Areas

My laboratory has made significant contributions to understanding the factors that influence the development of radio-resistant prostate cancer tumors. These concepts include the role of Bcl-2, COX2 and Akt, as well as the value of using small molecule inhibitors against these targets to restore radiation sensitization.

My most recent area of research focus has been exploring the biological significance of angiogenin, plasminogen activator inhibitor-1 and CXCL1 in human tumorigenesis. These studies have been conducted in collaboration with Dr. Steve Goodison. Upon unraveling the biologic significance, we have begun devising methodologies to target these molecules with the aim of introducing novel therapeutics to the clinic. Specifically, my laboratory played a major role in describing the biological effects of Bcl-2 on tumoral angiogenesis. Specifically, we went on to identify that Bcl-2 stimulates the expression of CXCL1 in tumor epithelial and tumor endothelial. Each of these preclinical observations has led to clinical evaluation. We are currently completing preclinical toxicology studies as we prepare to bring a novel therapeutic to the clinic in mid-2022.